SynthesisJournal of neurology2022
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review.
Synthesis in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review to explore patients' MS knowledge and MS risk knowledge.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Effectiveness of Single-Tablet Combination Therapy in Improving Adherence and Persistence and the Relation to Clinical and Economic Outcomes.Journal of health economics and outcomes research · 2024Pooled it
- Internet-delivered cognitive behavioural therapy programme to reduce depressive symptoms in patients with multiple sclerosis: a multicentre, randomised, controlled, phase 3 trial.The Lancet. Digital health · 2023Trial
- Polypharmacy, Potential Drug-Drug Interactions and Medication Non-Adherence in Patients with Multiple Sclerosis: A Longitudinal Study.Neurology and therapy · 2026Article
- A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing-Remitting Multiple Sclerosis.Neurology and therapy · 2026Article
- Clinical, demographic, and pharmacological predictors of medication adherence to disease-modifying therapies in multiple sclerosis: a multidimensional analysis of merged survey and claims data.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The COMPASS-MS Study on Implementing Digital Assessment and Treatment for Psychological Distress in Patients With Multiple Sclerosis: Protocol for a Real-World Longitudinal Study.JMIR research protocols · 2026Article
- Personality Traits and Their Association With Medication Non-Adherence in Patients With Multiple Sclerosis.CNS neuroscience & therapeutics · 2026Article
- Patient‑Reported Satisfaction in Relapsing-Remitting Multiple Sclerosis: Advantages of At‑Home Self‑Administered Subcutaneous Ofatumumab Versus Other High‑Efficacy Therapies.Drugs - real world outcomes · 2026Article
- The role of health literacy in medication adherence among people living with multiple sclerosis: a cross-sectional study in Isfahan, Iran.BMC neurology · 2026Article
- Comorbidities at MS Diagnosis and Their Association With Treatment Persistence: Real-World Clinical Data.Brain and behavior · 2026Article
- Differential Associations Between Perceived Social Support and Cognition in Older Adults With and Without Multiple Sclerosis.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2026Article
- Neuroinflammation and Mental Health in Multiple Sclerosis and Autoimmune Encephalitis: Bridging Biological Mechanisms and Psychosocial Factors.Archives of internal medicine research · 2026Article
- Health Literacy, Beliefs About Medication, and Medication Adherence in Patients With Multiple Sclerosis in Jordan: A Cross-Sectional Study.Health science reports · 2025Article
- Patient and healthcare provider experience of diroximel fumarate: considerations for selecting disease-modifying therapy.Neurodegenerative disease management · 2025Article
- Treatment Adherence in MS: Does Objective MS Knowledge and MS Risk Knowledge Matter in Relation to Perceived Disease-Modifying Therapy Benefits?Neurology and therapy · 2025Article
- Understanding Depression in People Living with Multiple Sclerosis: A Narrative Review of Recent Literature.Neurology and therapy · 2025Review
- Longitudinal Insights from Blended Hearing Care: Service Modality Choices, Support Received, and Satisfaction Ratings.Healthcare (Basel, Switzerland) · 2025Article
- Adherence to therapeutic recommendation in relapsing-remitting multiple sclerosis patients.Frontiers in immunology · 2025Article
- Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.Journal of neurology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with multiple sclerosis (MS) face challenges adhering to disease-modifying drug (DMD) treatment. Poor adherence to treatment reduces its clinical effectiveness which can adversely impact disease progression, MS-related hospitalisation, and mortality rates. Understanding the barriers to adherence is essential to addressing these issues in clinical practice and a consolidation of the literature had not yet been carried out. A systematic search was carried out using the electronic databases PsycINFO, and PubMed (Medline) using the search terms treatment compliance or treatment adherence and multiple sclerosis or MS. Studies included adults, with a diagnosis of relapsing-remitting MS (RRMS) (sample > 80% RRMS), taking a DMD. The studies used an adequate measurement of treatment adherence and analysed possible factors associated with adherence. A total of 349 studies were retrieved, of which 24 were considered eligible for inclusion. Overall adherence rates of the included studies ranged from 52 to 92.8%. Narrative synthesis revealed the most prevalent factors associated with adherence were age, gender, depression, cognition, treatment satisfaction, injection-site reactions, and injection anxiety. There was contradictory evidence for disability in association with treatment adherence. The findings should be used to inform the development of targeted patient support programs which improve treatment compliance. The review also highlights the opportunities for advancing research into treatment adherence in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.